Screener
Ligand Pharmaceuticals LGND Net debt / EBITDA
Net debt / EBITDA at other companies
Other financials
Where this comes from
Calculated from Ligand Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
FAQ
- What is Ligand Pharmaceuticals's net debt / EBITDA?
- Ligand Pharmaceuticals (LGND) reported net debt / EBITDA of 1× in Q2 2026.
- How has Ligand Pharmaceuticals's net debt / EBITDA changed year-over-year?
- Ligand Pharmaceuticals's net debt / EBITDA increased by 101.0% year-over-year, from -95.7× to 1×.
- What is the long-term trend for Ligand Pharmaceuticals's net debt / EBITDA?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's net debt / EBITDA has grown at a 39.5% compound annual growth rate (CAGR), from -0.4× to -2.3×.
- What does net debt / EBITDA mean?
- Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.
Ask your AI about Ligand Pharmaceuticals's net debt / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude